A Bridging Dose-Escalation Study of the Safety, Pharmacokinetic Properties, and Immunologic Effect of Subcutaneous L2-7001 (Recombinant Human Interleukin-2) in Patients Infected With HIV With CD4+ T-Cell Counts of 300 to 500 Cells/mm3 and Viral Burden Under 10,000 Copies/Ml on Active Antiretroviral Therapy (ART)
试验速览
- 阶段
- 1 期
- 入组人数
- 212
- 试验地点
- 23
研究概览
简要总结
The purpose of this study is to see if it is safe and effective to give HIV-positive patients L2-7001 (a type of interleukin-2) plus anti-HIV therapy. Interleukin-2 (IL-2) is a substance naturally produced by the body's white blood cells that plays an important role in helping the body fight infection. IL-2 may be able to boost the immune systems of people with HIV infection.
详细描述
This study takes place in two phases. Phase A consists of an open-label dose-escalation of L2-7001 through four dose levels. Ascending dose cohorts of five patients are studied. The safety and tolerability of L2-7001 is assessed in preparation for the second phase of the study and to estimate an MTD. Phase B involves randomization of 190 patients to (a) one of three dose levels of L2-7001 plus ART, (b) one of two dosing levels of Proleukin plus ART, or (c) ART alone. L2-7001 and Proleukin are given SC every 12 hours for the first 5 days of an 8-week cycle for three cycles. Serum IL-2 levels, soluble IL-2 receptor levels, and levels of pro-inflammatory cytokines are evaluated in 8 patients randomized to each treatment cohort of Phase B. All patients completing this phase of the protocol are eligible to be screened for enrollment in a maintenance use protocol which will allow for access to L2-7001.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients may be eligible for this study if they:
- •Are HIV-positive.
- •Have a viral load below 10,000 copies/ml.
- •Have a CD4 count between 300 and 500 cells/mm
- •Have been on stable anti-HIV therapy for 4 months. Patients must be taking at least 2 drugs, 1 of which must be a protease inhibitor or a nonnucleoside drug (NNRTI).
- •Are at least 18 years old.
- •Agree to use an effective barrier method of birth control, such as condoms, during the study.
排除标准
- •Patients will not be eligible for this study if they:
- •Have an AIDS-defining illness. (Patients who have had an AIDS-defining illness that was cured may still be eligible.)
- •Have an alcohol or drug abuse problem that the doctors feel would affect their ability to participate.
- •Have cancer requiring chemotherapy.
- •Have a history of autoimmune disease.
- •Have uncontrolled diabetes or certain thyroid problems.
- •Have mental illness or other serious medical condition that the doctors feel would affect their ability to participate.
- •Have received IL-2 in the past.
- •Have taken corticosteroids or certain medications that affect the immune system in the past 4 weeks.
- •Have taken hydroxyurea in the past 4 months.
- •Are pregnant or breast-feeding.